Abstract:Objective: To explore the clinical and laboratory characteristics of hematological tumors with different types of abnormalities in platelet derived growth factor β (PDGFRβ) gene. Methods: A retrospective analysis was carried out on 141 patients with abnormal long arm of chromosome 5 (5q) and comprehensive medical history data from Changhai Hospital Affiliated to Naval Medical University from 2009 to 2020, and their clinical data were collected. R-banding technique was used for chromosomal karyotyping analysis for the patient's bone marrow, and fluorescence in situ hybridization (FISH) was used to detect the PDGFRβ gene. The results of detection were divided into the amplification group, deletion group, and translocation group based on FISH signals. The three sets of data column crosstabs were statistically analyzed, and if the sample size was n >= 40 and the expected frequency T for each cell was >= 5, a Pearson test was used to compare the three groups of data. If N < 40 and any of the expected frequency T for each cell was < 5, a Fisher's exact test is used. Should there be a difference in the comparison results between the three sets of data, a Bonferroni method was further used to compare the data. Results: In total 98 patients were detected to have PDGFRβ gene abnormalities with the PDGFRβ probe, which yielded a detection rate of 69.50% (98/141). Among these, 38 cases (38.78%) had PDGFRβ gene amplifications, 57 cases (58.16%) had deletions, and 3 (3.06%) had translocations. Among the 98 cases, 93 were found to have complex karyotypes, including 37 cases from the amplification group (97.37%, 37/38), 55 cases from the deletion group (96.49%, 55/57), and 1 case from the translocation group (33.33%, 1/3). Analysis of three sets of clinical data showed no significant gender preponderance in the groups (P > 0.05). The PDGFRβ deletion group was mainly associated with myeloid tumors, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (P < 0.001). The PDGFRβ amplification group was more common in lymphoid tumors, such as multiple myeloma (MM) (P < 0.001). The PDGFRβ translocation group was also more common in myelodysplastic/myeloproliferative tumors (MDS/MPN). Conclusion: Tumors with PDGFRβ gene rearrangement may exhibit excessive proliferation of myeloproliferative tumors (MPN) and pathological hematopoietic changes in the MDS, and have typical clinical and hematological characteristics. As a relatively rare type of hematological tumor, in addition to previously described myeloid tumors such as MPN or MDS/MPN, it may also cover lymphoid/plasma cell tumors such as multiple myeloma and non-Hodgkin's lymphoma.

Myeloid Neoplasm with the Abnormality of PDGFRB Gene Secondary Interstitial Pneumonia: A Case Report

Pulmonary Benign Metastasizing Leiomyoma Presented As Acute Hypoxemic Respiratory Failure: A Case Report

Myeloid Tumors Accompanying Systemic Mastocytosis, Basophilia, and Abnormal Platelet-Derived Growth Factor Receptor Β

FIP1L1-PDGFRalpha Alone or with Other Genetic Abnormalities Reveals Disease Progression in Chronic Eosinophilic Leukemia but Good Response to Imatinib.

Secondary Mixed Phenotype Acute Leukemia Following Chemotherapy for Diffuse Large B-cell Lymphoma: a Case Report and Review of the Literature.

Eosinophil atypia in a myeloid/lymphoid neoplasm with PDGFRA rearrangement

Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia

A Case of Myeloid Neoplasm with Fip1l1-Pdgfra Rearrangement Without Marked Peripheral Blood Eosinophilia

[Clinical significance of PDGFRβ gene testing in hematological tumors]

Pulmonary Tumor with Notochordal Differentiation: a Case Report and Morphologic, Immunohistochemical and Molecular Study of Benign Notochordal Cell Tumor Originating in the Lung

Clinical and Genetic Features of a Patient with Myeloid Neoplasm in Association with PDGFRA and EVI1 Gene Rearrangements

Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib

Myeloproliferative Neoplasm with ETV6-ABL Rearrangement Conferred a Granulocyte Proliferation Bias

Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement t(8;13)(p11;q12): A case report and literature review

A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications

A Rare Pulmonary Myoepithelial Tumor with Novel TRPS1-PLAG1 Fusions

Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity

Case report: Simultaneous occurrence of primary pulmonary lymphoma and opportunistic infections in a patient with chronic myeloid leukemia

Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report

Primary EWS/PNET of the Lung with TP53 Germline and SKT11 Somatic Mutation: A Case Report and Review of the Literature

PCM1::JAK2 myeloproliferative neoplasm suggested by bone marrow histopathological features